Get the Stockscreener App
4.385
0.23%
-0.015
Astria Therapeutics Inc stock is traded at $4.385, with a volume of 21,080.
It is down -0.23% in the last 24 hours and up +7.60% over the past month.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
See More
Previous Close:
$4.40
Open:
$4.7
24h Volume:
21,080
Relative Volume:
0.06
Market Cap:
$291.20M
Revenue:
-
Net Income/Loss:
$-72.89M
P/E Ratio:
-1.812
EPS:
-2.42
Net Cash Flow:
$-68.47M
1W Performance:
-18.10%
1M Performance:
+7.60%
6M Performance:
-62.86%
1Y Performance:
-56.83%
1-Day Range:
$4.36
$4.70
1-Week Range:
$4.21
$5.36
52-Week Range:
$3.555
$12.92
Astria Therapeutics Inc Stock (ATXS) Company Profile
Name
Astria Therapeutics Inc
Sector
Industry
Phone
617-349-1971
Address
22 BOSTON WHARF ROAD, BOSTON
Compare ATXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
4.39 | 291.20M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.38 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
543.55 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
562.75 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.81 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
235.31 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jul-29-24 | Initiated | TD Cowen | Buy |
| Mar-28-23 | Initiated | Evercore ISI | Outperform |
Astria Therapeutics Inc Stock (ATXS) Latest News
10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey
Astria Therapeutics Inc (ATXS)’s Day in Review: Closing at 4.42, Up by 1.14 - DWinneX
Transcript : Astria Therapeutics, Inc. Presents at The Citizens JMP Life Sciences Conference 2025, May-07-2025 10 - marketscreener.com
Astria Therapeutics at Citizens JMP: Advancing HAE Treatments By Investing.com - Investing.com India
Astria Therapeutics at Citizens JMP: Advancing HAE Treatments - Investing.com Australia
Raymond James Financial Inc. Buys Shares of 79,044 Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Barclays PLC Boosts Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
(ATXS) Long Term Investment Analysis - news.stocktradersdaily.com
Astria Therapeutics Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Invesco Ltd. Has $161,000 Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics Announces Inducement Grants Under Nasdaq Lis - GuruFocus
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ATXS Stock News - GuruFocus
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Wall Street analysts’ outlook for Astria Therapeutics Inc (ATXS) - Sete News
Financial Metrics Check: Astria Therapeutics Inc (ATXS)’s Ratios for Trailing Twelve Months - DWinneX
Brokers Set Expectations for ATXS FY2025 Earnings - Defense World
Breaking down ATXS’s current quarter earnings estimates - uspostnews.com
Astria Therapeutics Announces Publication of Navenibart Phase 1a - GuruFocus
Astria Therapeutics reports progress in HAE drug trial By Investing.com - Investing.com India
Astria Therapeutics reports progress in HAE drug trial - Investing.com
Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology - Business Wire
Astria Therapeutics, Inc. (NASDAQ:ATXS) Holdings Increased by Legal & General Group Plc - Defense World
Astria Therapeutics (ATXS) to Release Quarterly Earnings on Thursday - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Position Increased by JPMorgan Chase & Co. - Defense World
Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference | ATXS Stock News - GuruFocus
Cantor Fitzgerald Upgrades Astria Therapeutics (NASDAQ:ATXS) to “Strong-Buy” - Defense World
Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference - Business Wire
Astria Therapeutics (ATXS) Receives Overweight Rating with Promi - GuruFocus
Cantor Fitzgerald Initiates Coverage of Astria Therapeutics (ATXS) with Overweight Recommendation - Nasdaq
Astria Therapeutics (ATXS) Receives Overweight Rating with Promising Prospects | ATXS Stock News - GuruFocus
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $26.60 Consensus Price Target from Analysts - Defense World
Ratios Revealed: Decoding Astria Therapeutics Inc (ATXS)’s Financial Health - DWinneX
Astria Therapeutics Inc (ATXS) stock analysis: A simple moving average approach - uspostnews.com
Geode Capital Management LLC Sells 2,770 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
ATXS’s Stock Dilemma: Astria Therapeutics Inc’s Market Performance and Outlook - investchronicle.com
Top Premarket Decliners - marketscreener.com
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Purchased by Vanguard Group Inc. - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Bought by American Century Companies Inc. - Defense World
KLP Kapitalforvaltning AS Takes Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Raymond James Financial Inc. Takes $707,000 Position in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Long Term Trading Analysis for (ATXS) - news.stocktradersdaily.com
Teacher Retirement System of Texas Makes New Investment in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics Grants $235K Worth of Stock Options to Strategic New Hires - Stock Titan
Analysts Set Astria Therapeutics, Inc. (NASDAQ:ATXS) PT at $26.60 - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Purchased by Swiss National Bank - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Acquired by Swiss National Bank - The AM Reporter
Charles Schwab Investment Management Inc. Increases Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
(ATXS) Investment Report - news.stocktradersdaily.com
Q1 EPS Estimates for Astria Therapeutics Cut by Wedbush - The AM Reporter
What is HC Wainwright’s Forecast for ATXS Q1 Earnings? - Defense World
Astria Therapeutics Inc Stock (ATXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.73%
1.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):